Cogent Biosciences (COGT) Expected to Announce Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Cogent Biosciences to post earnings of ($0.55) per share for the quarter.

Cogent Biosciences Stock Performance

Shares of Cogent Biosciences stock traded up $0.24 on Friday, hitting $5.87. The company had a trading volume of 1,011,472 shares, compared to its average volume of 1,259,321. The stock has a market capitalization of $668.33 million, a price-to-earnings ratio of -2.37 and a beta of 1.91. Cogent Biosciences has a 1 year low of $3.72 and a 1 year high of $12.61. The stock has a 50 day moving average of $5.86 and a 200-day moving average of $7.98.

Analysts Set New Price Targets

Several analysts have recently commented on COGT shares. Robert W. Baird lowered their target price on shares of Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. HC Wainwright dropped their target price on shares of Cogent Biosciences from $17.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, January 14th. Scotiabank initiated coverage on Cogent Biosciences in a research report on Friday, March 7th. They set a "sector outperform" rating and a $17.00 price target for the company. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a research report on Wednesday, February 26th. Finally, Piper Sandler raised Cogent Biosciences to a "strong-buy" rating in a research report on Friday, March 7th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $14.43.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.